Clinical Effects of Chymotrypsin Combined with Xilei Powder in Treatmen of Patients with Ulcerative Colitis and its Effect on Inflammatory Response and Immune Function
SONG Dong-xu,HE Hong-qin,ZHANG Wen-ling
Gastroenterological Surgery, Cangzhou People’s Hospital, Cangzhou (061000), China
Abstract:
Objective To observe the clinical effificacy of chymotrypsin combined with Xilei Powder retention enema therapy for treatment of ulcerative colitis (UC) and to investigate its effects on serum inflflammatory factors, Th17 cells and Treg cells. Methods The data of 158 patients with UC diagnosed in our hospital from Jan. 2013 to Jul. 2017 were collected. And they were assigned into treatment group and control group according to random number table. The patients in control group were treated with mesalazine enteric-coated tablets orally and retention enema, meanwhile gentamicin and flumethasone were added into the enema solution. And the patients in the treatment group were treated with chymotrypsin and Xilei Powder retention enema therapy based on treatment of the control group. The two groups of patients were divided into three subgroups of light, moderate and severe according to the Mayo score. To evaluate the clinical effificiency, Mayo score and endoscopic score were evaluated after two treatment sessions. The expression levels of ESR, CRP, TNF-α and IL-6 in peripheral blood were detected before and after treatment, and the number of Th17 cells and Treg cells were measured by flflow cytometer. Results After treatment, the levels of Mayo score and Baron score in the two groups were significantly lower than those before treatment, and the changes of the treatment group were more significant than those of the control group (P<0.05). And the difference was statistically signifificant (P<0.05). The expression levels of ESR, CRP, TNF-α, IL-6 and the number of Th17 cells were signifificantly positively correlated with UC grade, while the number of Treg cells was signifificantly negatively correlated with UC grade, and the difference was statistically signifificant (P<0.05). After treatment, the expression of ESR, CRP, TNF-α and IL-6 decreased. Meanwhile the number of Th17 cells decreased, but the number of Treg cells increased, and the changes of the treatment group were more obvious than those of the control group (P<0.05). Conclusion Chymotrypsin combined with Xilei Powder retention enema has a signifificant clinical effect, which can signifificantly reduce the inflflammatory response and regulate the immune function of UC patients.
